株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界のホジキンリンパ腫治療市場の将来動向

Global Hodgkins Lymphoma Therapeutics Market 2014-2018

発行 TechNavio (Infiniti Research Ltd.) 商品コード 310041
出版日 ページ情報 英文 79 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.77円で換算しております。
Back to Top
世界のホジキンリンパ腫治療市場の将来動向 Global Hodgkins Lymphoma Therapeutics Market 2014-2018
出版日: 2014年08月06日 ページ情報: 英文 79 Pages
概要

ホジキンリンパ腫(HL)とは、リンパ組織(人体の免疫系の一部)に生じるがんの一種と定義されています。ホジキンリンパ腫の正確な病因は不明ですが、免疫系を弱めるような病気にかかった場合に発症リスクが高くなります。ホジキンリンパ腫の場合、リンパ系内部の細胞量が劇的に増加し、リンパ系内部の各所に拡散し、リンパ球の感染症抑制機能が損なわれ、患者が感染症にかかりやすくなります。最も一般的な治療法は化学療法で、放射線治療がそれに続きます(化学療法のみの場合もあります)。この疾患の場合、外科手術は使用されません。全世界のホジキンリンパ腫関連市場の年平均成長率(CAGR)は、2013〜2018年に6.84%に達する、と推計されています。

当レポートでは、全世界のホジキンリンパ腫治療の関連市場について分析し、疾患の概要や市場構造、市場動向(今後5年間の予測値)、地域別の詳細動向、市場の促進・抑制要因とその影響力、主要企業のプロファイル、今後の市場機会などを調査・考察しております。

第1章 エグゼクティブ・サマリー

第2章 略語集

第3章 分析範囲

  • 市場概要
  • 主な製品・サービス
    • 製品のプロファイル

第4章 市場分析の手法

  • 市場分析のプロセス
  • 分析手法

第5章 イントロダクション

第6章 市場環境

  • 市場概況
  • 市場規模とその予測

第7章 世界保健機構(WHO)によるホジキンリンパ腫の分類

第8章 ホジキンリンパ腫の病期

第9章 ホジキンリンパ腫の化学療法のオプション

  • ファイブフォース分析

第10章 薬剤クラス別の市場分析

第11章 地域別の分析

第12章 購入基準

第13章 主要国の発症率・有病率

  • 米国
  • 英国

第14章 パイプライン製品の現状

第15章 市場の成長促進要因

第16章 促進要因とその影響力

第17章 市場の課題

第18章 促進要因・課題の影響力

第19章 市場の傾向

第20章 市場動向とその影響

第21章 ベンダー環境

  • 競争シナリオ
    • 近年の主な動向
    • 企業合併・買収(M&A)
  • 市場シェア分析
  • その他の著名なベンダー

第22章 主要ベンダーの分析

  • Bristol-Myers Squibb Co.
    • 企業概略
    • 事業概要
    • 製品分類
    • 部門別・地域別の売上高
    • 事業戦略
    • 主要データ
    • SWOT分析
  • F. Hoffmann La Roche Ltd.
  • Merck & Co. Inc.
  • Pfizer Inc.

第23章 その他の関連分析

図表一覧

目次
Product Code: IRTNTR3907

About Hodgkin's Lymphoma

Hodgkin's Lymphoma (HL) is defined as the cancer of the lymph tissue, which is part of our immune system. The exact etiology of HL is unknown. However, the risk of developing the condition is increased if a person suffers from a medical condition that weakens the immune system. In HL, cells in the lymphatic system grow unusually and may spread beyond the lymphatic system. The infection-fighting properties of the lymphocytes are lost, making the person more susceptible to infection. The main treatments used are chemotherapy, followed by radiotherapy or chemotherapy alone. Generally surgery is not used as a treatment for the condition.

TechNavio's analysts forecast the Global Hodgkin's Lymphoma Therapeutics market will grow at a CAGR of 6.84 percent over the period 2013-2018.

Covered in this Report

The Global Hodgkin's Lymphoma Therapeutics market can be divided into eight segments: Alkylating Antineoplastic Agents, Antibiotic Antineoplastic Agents, Antineoplastics Vinca Alkaloid Agents, Podophyllotoxin Derivative Antineoplastic Agents, Antimetabolite Antineoplastic Agents, Anthracycline Antineoplastic Agents, Antimicrotubular Antineoplastics, and Corticosteroids. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of HL that are available in the market.

TechNavio's report, the Global Hodgkin's Lymphoma Therapeutics Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Hodgkin's Lymphoma Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • Bristol Myers Squibb Co.
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co. Inc.
  • Pfizer Inc.

Other Prominent Vendors

  • 4SC AG
  • Actinium Pharmaceuticals Inc.
  • Aeterna Zentaris Inc.
  • Affimed Therapeutics AG
  • Hospira Inc.
  • Incyte Corp.
  • Novartis AG
  • Philogen S.p.A.
  • Seattle Genetics Inc.
  • Sigma-Tau Pharmaceuticals Inc.
  • Stemline Therapeutics Inc.
  • Teva Pharmaceutical Industries Ltd.

Key Market Driver

  • Improved Diagnostic Techniques.

For a full, detailed list, view our report.

Key Market Challenge

  • High Cost.

For a full, detailed list, view our report.

Key Market Trend

  • Increase in Awareness of HL.

For a full, detailed list, view our report.

Key questions answered in this report:

  • What will the market size be in 2018 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings
    • 03.2.1. Product Profiles

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Market Landscape

  • 06.1. Market Overview
  • 06.2. Market Size and Forecast

07. WHO Classification of Hodgkin's lymphoma

08. Stages of Hodgkin's Lymphoma

09. Chemotherapy Options for Hodgkin's Lymphoma

  • 09.1. Five Forces Analysis

10. Market Segmentation by Drug Class

11. Geographical Segmentation

12. Buying Criteria

13. Rate of Incidence and Prevalence

  • 13.1.1. US
  • 13.1.2. UK

14. Pipeline Snapshot

15. Market Growth Drivers

16. Drivers and their Impact

17. Market Challenges

18. Impact of Drivers and Challenges

19. Market Trends

20. Trends and their Impact

21. Vendor Landscape

  • 21.1. Competitive Scenario
    • 21.1.1. Key News
    • 21.1.2. Mergers and Acquisitions
  • 21.2. Market Share Analysis 2013
  • 21.3. Other Prominent Vendors

22. Key Vendor Analysis

  • 22.1. Bristol-Myers Squibb Co.
    • 22.1.1. Key Facts
    • 22.1.2. Business Overview
    • 22.1.3. Product Segmentation
    • 22.1.4. Sales by Geography
    • 22.1.5. Business Strategy
    • 22.1.6. Key Information
    • 22.1.7. SWOT Analysis
    • 22.1.8. Strengths
    • 22.1.9. Weaknesses
    • 22.1.10. Opportunities
    • 22.1.11. Threats
  • 22.2. F. Hoffmann La Roche Ltd.
    • 22.2.1. Key Facts
    • 22.2.2. Business Overview
    • 22.2.3. Business Segmentation
    • 22.2.4. Business Segmentation by Revenue 2012 and 2013
    • 22.2.5. Sales by Geography
    • 22.2.6. Business Strategy
    • 22.2.7. Key Information
    • 22.2.8. SWOT Analysis
    • 22.2.9. Strengths
    • 22.2.10. Weaknesses
    • 22.2.11. Opportunities
    • 22.2.12. Threats
  • 22.3. Merck & Co. Inc.
    • 22.3.1. Key Facts
    • 22.3.2. Business Overview
    • 22.3.3. Business Segmentation by Revenue 2013
    • 22.3.4. Business Segmentation by Revenue 2012 and 2013
    • 22.3.5. Sales by Geography
    • 22.3.6. Business Strategy
    • 22.3.7. Key Developments
    • 22.3.8. SWOT Analysis
    • 22.3.9. Strengths
    • 22.3.10. Weaknesses
    • 22.3.11. Opportunities
    • 22.3.12. Threats
  • 22.4. Pfizer Inc.
    • 22.4.1. Key Facts
    • 22.4.2. Business Overview
    • 22.4.3. Business Segmentation by Revenue 2013
    • 22.4.4. Business Segmentation by Revenue 2012 and 2013
    • 22.4.5. Sales by Geography
    • 22.4.6. Business Strategy
    • 22.4.7. Key Developments
    • 22.4.8. SWOT Analysis
    • 22.4.9. Strengths
    • 22.4.10. Weaknesses
    • 22.4.11. Opportunities
    • 22.4.12. Threats

23. Other Reports in this Series

List of Exhibits:

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Global Hodgkin's Lymphoma Therapeutics Market 2013-2018 (US$ million)
  • Exhibit 3: NCI Lymphoma Research Portfolio 2013
  • Exhibit 4: Global Hodgkin's Lymphoma Therapeutics Market Segmentation by Drug Class
  • Exhibit 5: Global Hodgkin's Lymphoma Therapeutics Market by Geographical Segmentation 2013
  • Exhibit 6: Bristol-Myers Squibb Co.: Product Segmentation (Based on Therapeutic Areas)
  • Exhibit 7: Bristol-Myers Squibb Co.: Sales by Geography 2013
  • Exhibit 8: Business Segmentation of F. Hoffmann-La Roche Ltd. 2013
  • Exhibit 9: F. Hoffmann-La Roche Ltd: Business Segmentation by Revenue 2012 and 2013
  • Exhibit 10: F. Hoffmann-La Roche Ltd: Sales by Geography 2013 (Pharmaceuticals Division)
  • Exhibit 11: F. Hoffmann-La Roche Ltd: Sales by Geography 2013 (Diagnostics Division)
  • Exhibit 12: Merck & Co. Inc.: Business Segmentation by Revenue 2013
  • Exhibit 13: Merck & Co. Inc.: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
  • Exhibit 14: Merck & Co. Inc.: Sales by Geography 2013
  • Exhibit 15: Pfizer Inc.: Business Segmentation by Revenue 2013
  • Exhibit 16: Pfizer Inc.: Business Segmentation by Revenue 2012 and 2013
  • Exhibit 17: Pfizer Inc.: Sales by Geography 2013
Back to Top